Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,541 to 3,560 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Dapivirine Vaginal Ring vs Placebo Vaginal Ring: Percentage of Participants With Pregnancy in Each Trial Arm Over the IP Use Period; | 43 of 1,306 20 of 652 | 0.2 points -1.6 to 1.8 | 1,958 | NCT01539226 Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women |
| Dapivirine Vaginal Ring vs Placebo Vaginal Ring: All Adverse Events | 1,147 of 1,306 561 of 652 | 1.8 points -1.3 to 5.1 | 1,958 | NCT01539226 Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women |
| Dapivirine Vaginal Ring vs Placebo Vaginal Ring: deaths from any cause | 2 of 1,306 3 of 652 | -0.3 points -1.2 to 0.2 | 1,958 | NCT01539226 Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women |
| Dapivirine Vaginal Ring vs Placebo Vaginal Ring: serious adverse events | 41 of 1,306 9 of 652 | 1.8 points 0.3 to 3.0 | 1,958 | NCT01539226 Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women |
| Integrated Protocol vs Current Protocol: Recovery Under the Integrated Program and the Standard Protocol | 910 of 1,100 682 of 857 | 3.1 points -0.3 to 6.7 | 1,957 | NCT01785680 Moderate Acute Malnutrition (MAM) and Severe Acute Malnutrition (SAM) in Sierra Leone |
| Integrated Protocol vs Current Protocol: deaths from any cause | 42 of 1,100 35 of 857 | -0.3 points -2.1 to 1.5 | 1,957 | NCT01785680 Moderate Acute Malnutrition (MAM) and Severe Acute Malnutrition (SAM) in Sierra Leone |
| PF-07321332 300 mg + Ritonavir 100 mg vs Placebo: Number of Participants With Progression to a Worsening Status in 1 or More Self-reported COVID-19 Associated Symptoms Through Day 28-mITT1 Population | 735 of 970 737 of 986 | 1.0 points -2.8 to 4.8 | 1,956 | NCT04960202 EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19 |
| Obeldesivir vs Placebo: serious adverse events | 2 of 979 4 of 976 | -0.2 points -0.9 to 0.4 | 1,955 | NCT05715528 Study of Obeldesivir in Nonhospitalized Participants With COVID-19 |
| Participants From Boceprevir Studies vs Participants From Narlaprevir Studies: Number of Participants That Discontinued the LTFU Due to SAEs | 19 of 1,907 0 of 47 | 1.0 points -6.6 to 1.6 | 1,954 | NCT00689390 Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063) |
| Participants From Boceprevir Studies vs Participants From Narlaprevir Studies: Number of Participants With Serious Adverse Events (SAEs) Reported During the LTFU | 136 of 1,907 2 of 47 | 2.9 points -7.2 to 6.2 | 1,954 | NCT00689390 Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063) |
| Participants From Boceprevir Studies vs Participants From Narlaprevir Studies: serious adverse events | 136 of 1,907 2 of 47 | 2.9 points -7.2 to 6.2 | 1,954 | NCT00689390 Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063) |
| Transdisciplinary Approach vs Multidisciplinary Approach: Depressive Symptoms | 24 of 545 95 of 1,408 | -2.3 points -4.4 to 0.0 | 1,953 | NCT03442322 Optimizing Care for Patients With Dementia |
| Dapivirine Vaginal Ring vs Placebo Vaginal Ring: HIV-1 Seroconversion According to Comprehensive HIV Testing Algorithm. | 82 of 1,302 61 of 650 | -3.1 points -5.8 to -0.6 | 1,952 | NCT01539226 Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women |
| Indomethacin Alone vs Indomethacin+Pancreatic Stent: deaths from any cause | 24 of 975 26 of 975 | -0.2 points -1.7 to 1.2 | 1,950 | NCT02476279 Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis |
| Indomethacin Alone vs Indomethacin+Pancreatic Stent: serious adverse events | 355 of 975 352 of 975 | 0.3 points -4.0 to 4.6 | 1,950 | NCT02476279 Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis |
| TICAGRELOR vs CLOPIDOGREL: Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization | 21 of 964 16 of 985 | 0.6 points -0.7 to 1.8 | 1,949 | NCT00391872 A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome |
| CHICA Control vs CHICA Asthma Module: Diagnosis Rate of Asthma | 54 of 937 87 of 1,010 | -2.9 points -5.2 to -0.5 | 1,947 | NCT01312805 Using Computers to Assist in the Treatment of Asthma in a Pediatric Setting |
| Intervention Group vs Delay Results Group: deaths from any cause | 2 of 966 2 of 978 | 0.0 points -0.6 to 0.6 | 1,944 | NCT03170362 PRIME Care (PRecision Medicine In MEntal Health Care) |
| Intervention Group vs Delay Results Group: serious adverse events | 76 of 966 70 of 978 | 0.7 points -1.6 to 3.1 | 1,944 | NCT03170362 PRIME Care (PRecision Medicine In MEntal Health Care) |
| IBD Cases With Mental Health Condition vs IBD Cases Without Mental Health Condition (Reference Group): Stream 2: Relative Risk of Bowel Symptoms (Quality of Life Indicator) | 148 of 295 473 of 1,648 | 21.5 points 15.4 to 27.5 | 1,943 | NCT05206734 Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health |
Code
curl "https://conductscience.org/api/comparisons/v1?page=178"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=178
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01539226-14e85045",
"title": "Dapivirine Vaginal Ring vs Placebo Vaginal Ring: Percentage of Participants With Pregnancy in Each Trial Arm Over the IP Use Period;",
"summary": "43 of 1306 against 20 of 652; risk difference 0.2 points, 95% interval -1.6 to 1.8; NCT01539226, Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women",
"record": "/library/comparisons/NCT01539226-14e85045",
"nct_id": "NCT01539226",
"kind": "outcome",
"participants": 1958,
"risk_difference": {
"value": 0.0022501150893939233,
"lower": -0.016019630753510244,
"upper": 0.0177108411303464
},
"group_1": "43 of 1,306",
"group_2": "20 of 652",
"difference": "0.2 points",
"interval": "-1.6 to 1.8",
"trial_title": "Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women"
},
{
"id": "NCT01539226-5a7057a2",
"title": "Dapivirine Vaginal Ring vs Placebo Vaginal Ring: All Adverse Events",
"summary": "1147 of 1306 against 561 of 652; risk difference 1.8 points, 95% interval -1.3 to 5.1; NCT01539226, Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women",
"record": "/library/comparisons/NCT01539226-5a7057a2",
"nct_id": "NCT01539226",
"kind": "outcome",
"participants": 1958,
"risk_difference": {
"value": 0.017824763479551642,
"lower": -0.013084664518944873,
"upper": 0.05101113351819796
},
"group_1": "1,147 of 1,306",
"group_2": "561 of 652",
"difference": "1.8 points",
"interval": "-1.3 to 5.1",
"trial_title": "Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=179",
"request_id": "JBxWUtRbdPNIfTpB"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant